Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome

Table 1 Summary of patients attending the national paediatric cryopyrin associated periodic fever syndrome service

Total number of patients who ever attended the GOSH CAPS service		39
Total number of patients included for study		20
Total number of patients with negative NLRP3 mutation		4
Total number of doses of canakinumab ever received per patient	Median	14
	Range	7–41 doses
Age	Median	9 years
Age	Range	4–14 years
Gender	Male	10
Gender	Female	10

CAPS Cryopyrin associated periodic fever syndrome, GOSH Great Ormond Street Hospital

ISSN: 1546-0096